Recent developments highlight Microbot Medical's progress in commercialization, regulatory clearances, patent expansions, and analyst coverage.

• Microbot Medical expanded its commercial team ahead of the anticipated U.S. launch of the LIBERTY Endovascular Robotic System [N11].
• The company secured a key patent in China for the LIBERTY system, enhancing its intellectual property portfolio [N8].
• Microbot received FDA clearance for the LIBERTY Robotic System, supporting its commercialization efforts [N6].
• Multiple financial analysts, including B. Riley Securities, Roth Capital, and HC Wainwright & Co., initiated or reiterated buy recommendations for Microbot Medical [N1][N2][N3][N5].
• Microbot was selected for preliminary inclusion in the Russell Microcap® Index, reflecting growing market recognition [N12].
• The company obtained a new U.S. patent expanding the LIBERTY system market, potentially strengthening its competitive position [N7].

The bull case for Microbot Medical centers on successful commercialization and market adoption of the LIBERTY® Endovascular Robotic Surgical System. FDA clearance and key patent grants in the U.S. and China support the company's intellectual property position and market potential. Expansion of the commercial team and positive analyst coverage indicate growing market interest. If Microbot can establish efficient manufacturing, secure reimbursement, and gain acceptance among medical professionals, it could build a sustainable business model and transition toward profitability.

The bear case involves risks related to Microbot's limited operating history as a commercial-stage company and its lack of revenue generation through 2025. The company faces significant challenges in scaling manufacturing through third parties, obtaining further regulatory approvals, and achieving market acceptance. Reimbursement uncertainties and competition from established medical device companies may impede sales growth. Additionally, the need for substantial additional funding to support operations and commercialization efforts presents financial risks. Failure to address these challenges could materially harm the company's business and financial condition.

Microbot Medical's moat is primarily based on its proprietary LIBERTY® Endovascular Robotic Surgical System technology and its intellectual property portfolio, including key patents in major markets such as the U.S. and China. The company's focus on robotic surgical systems for endovascular procedures positions it in a specialized niche with potential barriers to entry due to regulatory requirements, manufacturing complexity, and the need for clinical acceptance. However, the moat is challenged by the company's limited commercial operating history, reliance on third-party manufacturers, and competition from established medical device companies with potentially superior or equivalent technologies.

• Lack of Revenue and Profitability: Microbot has not generated significant revenues and expects to continue incurring operating losses for the foreseeable future, with no assurance of achieving or sustaining profitability.
• Manufacturing and Supply Risks: The company relies on third-party manufacturers with limited experience in commercial-scale production, facing risks related to capacity, quality, regulatory compliance, and timely delivery.
• Regulatory and Market Acceptance Risks: Successful commercialization depends on obtaining necessary regulatory clearances and broad acceptance by medical professionals, which is uncertain and may be affected by safety, efficacy, and cost considerations.
• Reimbursement Risks: Adequate reimbursement from government and private payors is uncertain and critical for adoption; failure to secure or maintain reimbursement could limit sales growth.
• Capital and Funding Risks: Microbot expects to require additional funding to support commercialization and operations; inability to raise capital on acceptable terms could delay or curtail business plans.

• Microbot Medical Inc. is a medical device company focused on the LIBERTY® Endovascular Robotic Surgical System as its sole product.
• The company shifted its focus primarily from research and development to commercialization of the LIBERTY system in 2025.
• Microbot has not recognized any revenues from product sales through December 31, 2025, and does not anticipate significant revenues until successful commercialization of LIBERTY or other future products.
• The company has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future due to sales, marketing, research, development, and regulatory activities related to LIBERTY and other product candidates.
• Microbot relies on third-party manufacturers for production and has limited experience in manufacturing commercial-scale products.
• The company faces risks related to manufacturing capacity, regulatory compliance, and the ability to meet production and delivery schedules.
• Market acceptance of LIBERTY depends on medical community perception of safety, efficacy, cost-effectiveness, and competitive advantages over existing devices.
• Microbot must establish brand recognition and competitive advantages to support market uptake.
• The company faces risks related to reimbursement levels from government and private payors, which may affect sales growth.
• Microbot's financial position as of December 31, 2025, includes cash and equivalents of $3.9 million, short-term investments of $74.68 million, current assets of $79.82 million, and current liabilities of $3.42 million, resulting in a strong current ratio of 23.33 and cash ratio of 22.97.
• Net loss for the fiscal year ended December 31, 2025, was $13.14 million with basic and diluted EPS of -$0.29 per share.
• The company expects to need additional funding to continue transitioning to a profitable commercial enterprise and to build a sustainable business model.
• Microbot has expanded its commercial team ahead of the anticipated U.S. launch of the LIBERTY system.
• The company has secured key patents for the LIBERTY system in China and the U.S., expanding its market potential.
• Microbot has received FDA clearance for the LIBERTY Robotic System and is pursuing further regulatory approvals.
• Multiple reputable financial analysts have initiated or reiterated buy recommendations on Microbot Medical.
• The company is listed on the NASDAQ Capital Market under the ticker MBOT.